Gefitinib (AstraZeneca, Newark, DE, USA) is the first targeted drug to be approved for
advanced non-small cell lung cancer (NSCLC) that failed to respond to chemotherapy. It has …

Gefitinib is a small molecule tyrosine kinase inhibitor of epidermal growth factor receptor
(EGFR). Since 2004, it was clear that a substantial proportion of non-small-cell lung cancers …

Purpose The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such
as gefitinib, exhibit up to a 70% response rate against non-small cell lung cancer (NSCLC) …

Purpose: To determine if tumor regression following treatment with gefitinib correlates with
the presence of sensitizing mutations in epidermal growth factor receptor (EGFR). Patients …

8101 Background: Somatic mutations in the epidermal growth factor receptor (EGFR) gene
are associated with the therapeutic response to EGFR tyrosine kinase inhibitors (EGFR …

19072 Background: Non-small cell lung cancer (NSCLC) patients with epidermal growth
factor receptor (EGFR) mutation show excellent response to gefitinib, but eventually develop …

Abstract Background The Japan Guidelines of Lung Cancer Therapy recommend epidermal
growth factor receptor-tyrosine kinase inhibitors as a first-line therapy for advanced/recurrent …

In advanced nonsmall cell lung cancer (NSCLC), the epidermal growth factor receptor
(EGFR) is a major therapeutic target. Activating EGFR mutations, including either an in …

19075 Background: Probability of clinical benefit from EGFR tyrosine kinase inhibitors in
previously treated NSCLC pts is strongly associated with the presence of EGFR mutation …

Epidermal growth factor receptor (EGFR) mutation is a favorable prognostic factor of non-
small cell lung cancer (NSCLC). In the majority of patients with EGFR mutations, clinical …